Benefits
Bladder control
In a 12-week randomized, double-blind, placebo-controlled trial of this blend in 120 women, the supplemented group improved from its own starting point on urination frequency, urgency, leakage episodes, night-time urination and an overall symptom scale. The placebo group also improved significantly on three of those same measures. The published summary reports each group against its own baseline rather than a head-to-head comparison, the trial was funded by the ingredient's manufacturer, and it has not been repeated independently.
Urinary comfort
Pumpkin seed has a long history of traditional use for urinary comfort. Note that the branded blend itself has only been trialled in women; there is no trial of this blend in men, and in a one-year placebo-controlled trial in 1,431 men, a different pumpkin seed extract taken at the same 500 mg twice-daily dose was no better than placebo.
Soy germ isoflavones
The soy germ component supplies isoflavones, plant compounds with weak oestrogen-like activity. A role for them in the tissues involved in bladder control is a proposal rather than a finding: the only trial of this blend measured urinary symptoms and quality of life, not pelvic tissue.
Mechanism of action
Bladder-muscle support
Pumpkin seed contains phytosterols, and these have been proposed as the constituents responsible for its effects on urinary comfort. The mechanism is unresolved: investigators who tested pumpkin seed oil in overactive bladder report that the molecules responsible remain to be identified.
Isoflavone support
Soy germ isoflavones bind weakly to oestrogen receptors. An oestrogen-related effect on urinary tissue is a hypothesis for how the soy component might contribute; it has not been demonstrated in people taking this blend.
Clinical trials
Randomized, double-blind, placebo-controlled trial of the pumpkin seed plus soy germ extract blend, 500 mg twice daily for 12 weeks. (Shim B, Jeong H, Lee S, Hwang S, Moon B, Storni C. Journal of Functional Foods 2014;8:111-117, doi:10.1016/j.jff.2014.03.010. Not indexed in PubMed.) Funded by Frutarom Switzerland Ltd., which sells the ingredient; one of the authors worked for the company.
120 women aged 35 to 70 with overactive bladder-related voiding dysfunction. No men were enrolled.
After 12 weeks the supplemented group improved significantly from baseline on urination frequency, urgency, incontinence frequency, maximum urgency score, night-time urination frequency and an overall symptom scale. The placebo group also improved significantly on urination frequency, incontinence frequency and the symptom scale. No adverse events or abnormal safety laboratory values were reported in either group.